Gilbert Cisneros Sells Shares of Medtronic plc $MDT

Key Points

  • Gilbert Cisneros sold Medtronic plc ($MDT) stock ($1,001 - $15,000).
  • The trade was disclosed by a member of the House.
  • $MDT last traded around $80.20.
Congressional trading track record

Gilbert Cisneros vs. the S&P 500

YTD return -1.4% hypothetical
All-time return -1.0% S&P 500 +93.0%
vs. S&P 500 -94.0% behind the index

Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.

Gilbert Cisneros, a member of the House, sold $1,001 - $15,000 of Medtronic plc ($MDT) stock on 2026-05-15, according to a periodic transaction report filed under the STOCK Act. Disclosures are filed after the trade and reflect a dollar range, not an exact amount.

Medtronic plc ($MDT) Stock

Last price$80.20
Market cap$102.97B
P/E ratio21.50
Forward P/E12.52
PEG ratio1.58
Beta0.60
52-week low$73.31
52-week high$106.33
50-day MA$80.71
200-day MA$92.17
Debt-to-equity0.57

Medtronic plc Earnings

EPS (ttm)$3.73
Revenue (ttm)$36.36B
Revenue growth9.9%
Net margin13.2%
Return on equity9.9%
Next earningsAug 18, 2026

Medtronic plc Dividend

Annual dividend$2.88
Dividend yield359.00%
Payout ratio76.1%
Ex-dividend dateJun 26, 2026

Analysts Set New Price Targets

ConsensusBuy
Average target$98.00
High target$121.00
Low target$78.00
Analysts covering26

About Medtronic plc

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems and sensors, and InPen, a smart insulin pen. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.

ExchangeNYSE
SectorHealthcare
IndustryMedical Devices
HeadquartersGalway, Ireland
CEOMr. Geoffrey Straub Martha
Employees95,000

See Also

This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.